Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Vascular Diseases 1Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Multiple Myeloma 1Lymphoproliferative Disorders 1Lymphoma 1Lymphatic Diseases 1Immunoproliferative Disorders 1Hemorrhagic Disorders 1Hematologic Diseases 1Cardiovascular Diseases 1Blood Protein Disorders 1

Interventions

Brentuximab Vedotin 21Cyclophosphamide 17Rituximab 11fludarabine 9Mycophenolic Acid 9pirtobrutinib 7dacetuzumab 7Busulfan 7fludarabine phosphate 6Tacrolimus 6Melphalan 6Whole-Body Irradiation 5Doxorubicin 5Vincristine 4Prednisone 4Mesna 4Etoposide 4Bone Marrow Transplantation 4Bendamustine Hydrochloride 4ibrutinib 3Thiotepa 3Sirolimus 3Cyclosporine 3Bortezomib 3ponatinib 2Vorinostat 2Stem Cell Transplantation 2Rifampin 2Platelet Transfusion 2Peripheral Blood Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × ficlatuzumab × Lymphoid × Clear all
NCT00725634 2014-01-27

P05538

AVEO Pharmaceuticals, Inc.

Phase 1 Completed
41 enrolled
LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡